Objective To investigate the efficacy and safety of Aidi Injection combined with FOLFOX-4 chemotherapy in the treatment of advanced colorectal cancer.Methods Total 60 patients with advanced colorectal cancer admitted to our hospital from January 2022 to August 2023 were selected and divided into control group and study group by random number table method,with 30 cases in each group.The control group was given FOLFOX-4 chemotherapy regimen,and the study group was given Addy Injection on the basis of FOLFOX-4 chemotherapy regimen.The clinical efficacy,adverse reactions,immune function in-dicators(CD4+,CD8+,CD4+/CD8+and NK cells)and serum tumor markers of carcinoembryonic antigen(CEA),glycoantigen 19-9(CA19-9)and glycoantigen 242(CA242)were compared between the two groups.Results The disease control rate and remission rate of the study group were higher than those of the control group(P＜0.05).After treatment,the cell ratios of CD4+,CD4+/CD8+,NK in the study group were higher than those in the control group,and CD8+in the study group was lower than that in the control group(P＜0.05).After treatment,levels of CEA,CA19-9 and CA242 in the study group were lower than those in the control group(P＜0.05).The incidence of hematological toxicity,digestive sys-tem reaction and sensory neuropathy in the study group was lower than that in the control group(P＜0.05).Conclusion Aidi Injection combined with FOLFOX-4 chemotherapy regimen in the treatment of advanced colorectal cancer can improve clinical efficacy,regulate the immune function of patients,reduce the levels of serum tumor markers and the risk of adverse reactions.
NETL
NSTL
万方数据
